76. Use of a double stranded nucleic acid molecule according to any of claims 1-71, or a composition according to claim 72 in the manufacture of a medicament~~A method~~ for the ~~treatment of a subject in need of~~ treatment for a disease or disorder or symptom or condition associated with the expression of a target gene in a subject in need thereof; ~~comprising administering to the subject an amount of a double stranded nucleic acid molecule of any of claims 1-71, or a composition according to claim 72~~ wherein said double stranded nucleic acid molecule or said composition is to be administered in an amount effective to down regulate gene expression, and wherein the gene encodes a RNA having a polynucleotide sequence set forth in any one of SEQ ID NOS: 1-12.

77. The ~~method~~ use of claim 76, wherein the disease or injury is selected from the group consisting of chronic or acute aseptic inflammation, neuropathic pain, primary graft failure, ischemia-reperfusion injury, reperfusion injury, reperfusion edema, allograft dysfunction, pulmonary reimplantation response and primary graft dysfunction (PGD) in organ transplantation.

78. The ~~method~~ use of claim 77, wherein the disease or injury comprises primary graft dysfunction (PGD) in organ transplantation.

79. The ~~method~~ use of claim 78, wherein said organ transplantation comprises lung transplantation.

80. ~~A method~~ Use of a double stranded nucleic acid molecule according to any of claims 1-71, or a composition according to claim 72 in the manufacture of a medicament for treating or preventing the incidence or severity of a posttransplantational complication selected from the group consisting of primary graft failure, ischemia-reperfusion injury, reperfusion injury, reperfusion edema, allograft dysfunction, pulmonary reimplantation response, primary graft dysfunction (PGD), in a subject in need thereof; wherein the complication is associated with expression of a gene encoding a RNA having a polynucleotide sequence set forth in any one of SEQ ID NOS: 1-12; ~~, the method comprising~~ wherein the subject is to be administered ~~administering to the subject~~ a prophylactically or therapeutically effective amount of ~~said~~a double stranded nucleic acid molecule ~~of any of claims 1-71~~, or ~~a~~ said composition ~~according to claim 72 in an amount effective~~ to down regulate the gene expression.

81. ~~A method~~ Use of a double stranded nucleic acid molecule of any of claims 1-71, or a composition according to claim 72 in the manufacture of a medicament for reducing acute or chronic inflammation in a subject in need thereof; wherein the inflammation is associated with expression of a gene encoding a RNA having a polynucleotide sequence set forth in any one of SEQ ID NOS: 1-12; ~~, the method comprising administering to the subject a therapeutically effective amount of~~wherein the subject is to be administered with ~~said a~~ double stranded nucleic acid molecule ~~of any of claims 1-71~~, or ~~a~~ said composition ~~according to claim 72~~ in an amount effective to down regulate gene expression.